1. FDA approved Edwards Lifesciences’ SAPIEN 3 TAVR for asymptomatic severe aortic stenosis (AS).
2. Early TAVR showed lower rates of death, stroke, or unplanned cardiovascular hospitalization vs. clinical surveillance.
3. The EARLY TAVR trial data was published in The New England Journal of Medicine.
4. Current guidelines recommend watchful waiting, but symptom onset in AS patients can be abrupt.

Source: Edwards Lifesciences